Video

Janet Hampton on the Distress Thermometer Study Results

Author(s):

Janet Hampton, RN, BS

Janet Hampton University of Michigan Health System Cancer Center Explains Distress Thermometer Study Results

Janet Hampton, RN, BS, OCN® from the University of Michigan Health System Cancer Center Explains Distress Thermometer Study Results

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content
Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
April 25th 2025

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Jennifer Chan, MD, MPH
April 25th 2025

FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Opens the Door to a New Standard Option

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 17th 2025

Companion Diagnostic Nets European IVDR Certification for Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.
April 12th 2025

The OncFive: Top Oncology Articles for the Week of 4/6